|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.|
|Rapid review commissioned||28/05/2013|
|Rapid review completed||28/06/2013|
|Rapid review outcome||Full Pharmacoeconomic Assessment Not Recommended|
Linaclotide (Constella®) is to be reimbursed under the Community Drugs Schemes subject to conditions.